Latest Conference Articles

New phase 1/2 data shows AAV-RGPR may benefit a previously untreated population of inherited retina disease boys and young men.

A look at how primary care patients begin to present with diabetic retinopathy risk.

New PANORAMA findings could give ophthalmologists confidence in longer time between administrations after year 2.

New research shows patients with both conditions have greater levels of particular cytokines and metabolic proteins.

Where do investigators go next with the 8000-plus COPD patient research?

Both dosage groups of the study drug achieved at least a 50-meter increase from baseline to week 24 on the six-minute walk distance test.

Treatment with treprostinil of up to 12 breaths per session four-times per data was well-tolerated, with a safety profile consistent with previous studies.

In an era of triple therapy combinations, what might a tailored approach look like?

New findings from the 8000-plus patient ETHOS trial shows triple inhaler therapy siginificantly betters patient mortality and symptoms over 52 weeks versus dual therapy.

New research from ARVO 2020 suggests patients with diabetic eye disease can still experiences losses in visual acuity, even with glycemic control.

A survey of 19 patients with hereditary retinitis pigmentosa details the impact of the disease on the quality of life and daily activity of patients and caregivers.

Women with recent gestational diabetes who use the intervention see less retention of weight than those who do not use the intervention.

An analysis of data from 5 PIONEER trials is shedding new light on the impact of oral semaglutide based on background glucose-lowering therapy.

The drug also reduced the risk of myocardial infarction and stroke.

Taking testosterone while enrolled in a lifestyle program reduces glucose levels and risk of type 2 diabetes.

Discussing how advances in care and therapeutic agents have impacted the management of diabetes in 2020.

Gauging patient wellbeing prior to intravitreal injections may help inform clinicians as to who may fare worse with the treatment.

Todd Hobbs, MD, breaks down research presented at ADA 2020.

Discussing an analysis of retrospective claims data to examine the incidence of herpes zoster in patients with T2DM and how it impacts their diabetes.

Lead investigator of VERTIS-CV discusses results of the phase 3 trial examining ertugliflozin's impact on cardiovascular health.

A breakdown of a new 12-month, phase 1b/2 assessment of the RNA therapy in patients with LCA10.

The prevention of type 2 diabetes is possible and has important clinical benefits.

Not all youth and young adults with diabetes are directly benefiting from the increased availability of diabetes technology, newer therapies, and the use of more aggressive glycemic targets.

An analysis of nearly 8k veterans has found use of metformin was associated with a reduction in PTSD symptoms.

A new assessment shows about 60% of treatment-naive patients are not prescribed the most common drug class within 1 year of secondary edema.

An analysis of the DECLARE-TIMI 58 trial suggests dapagliflozin use could reduce the risk of fast decline in eGFR.

Examining the results of MEX0114, a phase 2 trial evaluating the use of ladarixin in patients with new-onset type 1 diabetes.

An investigator provides an update on the TEDDY study.